Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Omeros CorporationNASDAQ: OMER

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 63.51M shares rose 9.4% year over year, ahead of the +8.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.4% holds above the trailing-twelve-month pace of +8.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.51M+0.0% QoQ
Last fiscal yearDec 2025
63.51M+9.2% YoY
LTMMar 2026
62.97M+8.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.4%——
1 year+9.2%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
63.51M USD
Year-over-year change
+9.2%
4-year CAGR
+0.5%

Weighted Avg Shares (Diluted) vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 weighted avg shares (diluted) of 62.97M shares is the 8th highest of the 11 companies compared; the peer median is 78.76M shares.
  • Its year-over-year change of +8.5% is the 5th highest of 11, against a peer median of +5.1%.
  • Over three fiscal years its annual growth of +0.4% compares with a peer median of +9.0%.
OMER Competitors Peer median
Weighted Avg Shares (Diluted) for OMER and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.59M +22.4%+19.7%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
OMEROmeros CorporationLTM Mar 202662.97M +8.5%+0.4%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+8.2%
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
NKTRNektar TherapeuticsLTM Jun 202623.04M +63.6%+10.6%
Peer median (excluding OMER) 78.76M+5.1%+9.0%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.39M0000
Gross Profit(1.39M)0000
Gross Margin—————
Research & Development118.78M112.72M114.87M119.52M81.3M
Selling, General & Admin53.46M50.67M49.66M49.74M41.5M
Operating Expenses172.23M163.39M164.53M169.26M122.8M
Depreciation & Amortization1.39M952K920K950K964K
EBITDA(170.49M)(158.38M)(143.16M)(157M)(1.83M)
EBITDA Margin—————
Operating Income(173.62M)(163.39M)(164.53M)(169.26M)(122.8M)
Operating Margin—————
Interest Income17.93K4.06M16.34M11.3M5.06M
Interest Expense19.67M22.7M30.84M24.68M0
Other Income / Expenses(17.93M)(18.64M)(10.39M)(13.37M)120M
Income Before Tax(191.55M)(182.03M)(174.92M)(182.63M)(2.8M)
Pre-Tax Margin—————
Income Tax Expense00002.01M
Net Income(111.41M)47.42M(117.81M)(156.82M)(3.35M)
Net Margin—————
EPS (Basic)3.120.46(1.88)(2.70)(0.05)
EPS (Diluted)3.120.46(1.88)(2.70)(0.05)
Weighted Avg Shares62.34M62.74M62.74M58.17M63.51M
Weighted Avg Shares (Diluted)62.34M62.74M62.74M58.17M63.51M

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.